Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

Tailoring early-phase clinical trial design to address multiple research objectives.

Wages NA, Slingluff CL Jr, Bullock TN, Petroni GR.

Cancer Immunol Immunother. 2019 Dec 5. doi: 10.1007/s00262-019-02442-5. [Epub ahead of print]

PMID:
31807879
2.

Diacylglycerol Lipase-β Is Required for TNF-α Response but Not CD8+ T Cell Priming Capacity of Dendritic Cells.

Shin M, Buckner A, Prince J, Bullock TNJ, Hsu KL.

Cell Chem Biol. 2019 Jul 18;26(7):1036-1041.e3. doi: 10.1016/j.chembiol.2019.04.002. Epub 2019 May 16.

PMID:
31105063
3.

Impaired enolase 1 glycolytic activity restrains effector functions of tumor-infiltrating CD8+ T cells.

Gemta LF, Siska PJ, Nelson ME, Gao X, Liu X, Locasale JW, Yagita H, Slingluff CL Jr, Hoehn KL, Rathmell JC, Bullock TNJ.

Sci Immunol. 2019 Jan 25;4(31). pii: eaap9520. doi: 10.1126/sciimmunol.aap9520.

4.

Modulation of NKG2D, NKp46, and Ly49C/I facilitates natural killer cell-mediated control of lung cancer.

Shi L, Li K, Guo Y, Banerjee A, Wang Q, Lorenz UM, Parlak M, Sullivan LC, Onyema OO, Arefanian S, Stelow EB, Brautigan DL, Bullock TNJ, Brown MG, Krupnick AS.

Proc Natl Acad Sci U S A. 2018 Nov 13;115(46):11808-11813. doi: 10.1073/pnas.1804931115. Epub 2018 Oct 31.

5.

Formation and phenotypic characterization of CD49a, CD49b and CD103 expressing CD8 T cell populations in human metastatic melanoma.

Melssen MM, Olson W, Wages NA, Capaldo BJ, Mauldin IS, Mahmutovic A, Hutchison C, Melief CJM, Bullock TN, Engelhard VH, Slingluff CL Jr.

Oncoimmunology. 2018 Aug 6;7(10):e1490855. doi: 10.1080/2162402X.2018.1490855. eCollection 2018.

6.

Deciphering T Cell Immunometabolism with Activity-Based Protein Profiling.

Borne AL, Huang T, McCloud RL, Pachaiyappan B, Bullock TNJ, Hsu KL.

Curr Top Microbiol Immunol. 2019;420:175-210. doi: 10.1007/82_2018_124. Review.

PMID:
30128827
7.

Indoleamine-2,3-Dioxygenase in Non-Small Cell Lung Cancer: A Targetable Mechanism of Immune Resistance Frequently Coexpressed With PD-L1.

Volaric A, Gentzler R, Hall R, Mehaffey JH, Stelow EB, Bullock TN, Martin LW, Mills AM.

Am J Surg Pathol. 2018 Sep;42(9):1216-1223. doi: 10.1097/PAS.0000000000001099.

PMID:
29901571
8.

IDO expression in breast cancer: an assessment of 281 primary and metastatic cases with comparison to PD-L1.

Dill EA, Dillon PM, Bullock TN, Mills AM.

Mod Pathol. 2018 Oct;31(10):1513-1522. doi: 10.1038/s41379-018-0061-3. Epub 2018 May 25.

9.

Evaluation of SAS1B as a target for antibody-drug conjugate therapy in the treatment of pancreatic cancer.

Knapp KA, Pires ES, Adair SJ, Mandal A, Mills AM, Olson WC, Slingluff CL Jr, Parsons JT, Bauer TW, Bullock TN, Herr JC.

Oncotarget. 2018 Jan 4;9(10):8972-8984. doi: 10.18632/oncotarget.23944. eCollection 2018 Feb 6.

10.

CD47 Blockade as an Adjuvant Immunotherapy for Resectable Pancreatic Cancer.

Michaels AD, Newhook TE, Adair SJ, Morioka S, Goudreau BJ, Nagdas S, Mullen MG, Persily JB, Bullock TNJ, Slingluff CL Jr, Ravichandran KS, Parsons JT, Bauer TW.

Clin Cancer Res. 2018 Mar 15;24(6):1415-1425. doi: 10.1158/1078-0432.CCR-17-2283. Epub 2017 Dec 29.

11.

Focused Ultrasound Immunotherapy for Central Nervous System Pathologies: Challenges and Opportunities.

Curley CT, Sheybani ND, Bullock TN, Price RJ.

Theranostics. 2017 Aug 23;7(15):3608-3623. doi: 10.7150/thno.21225. eCollection 2017. Review.

12.

Immunotherapy for hepatocellular carcinoma patients: is it ready for prime time?

Obeid JM, Kunk PR, Zaydfudim VM, Bullock TN, Slingluff CL Jr, Rahma OE.

Cancer Immunol Immunother. 2018 Feb;67(2):161-174. doi: 10.1007/s00262-017-2082-z. Epub 2017 Oct 20. Review.

PMID:
29052780
13.

The Relationship Between Mismatch Repair Deficiency and PD-L1 Expression in Breast Carcinoma.

Mills AM, Dill EA, Moskaluk CA, Dziegielewski J, Bullock TN, Dillon PM.

Am J Surg Pathol. 2018 Feb;42(2):183-191. doi: 10.1097/PAS.0000000000000949.

PMID:
28914717
14.

TNF-receptor superfamily agonists as molecular adjuvants for cancer vaccines.

Bullock TN.

Curr Opin Immunol. 2017 Aug;47:70-77. doi: 10.1016/j.coi.2017.07.005. Epub 2017 Jul 24. Review.

15.

Mitochondrial dysregulation and glycolytic insufficiency functionally impair CD8 T cells infiltrating human renal cell carcinoma.

Siska PJ, Beckermann KE, Mason FM, Andrejeva G, Greenplate AR, Sendor AB, Chiang YJ, Corona AL, Gemta LF, Vincent BG, Wang RC, Kim B, Hong J, Chen CL, Bullock TN, Irish JM, Rathmell WK, Rathmell JC.

JCI Insight. 2017 Jun 15;2(12). pii: 93411. doi: 10.1172/jci.insight.93411. eCollection 2017 Jun 15.

16.

Lineage-Specific Metabolic Properties and Vulnerabilities of T Cells in the Demyelinating Central Nervous System.

Seki SM, Stevenson M, Rosen AM, Arandjelovic S, Gemta L, Bullock TNJ, Gaultier A.

J Immunol. 2017 Jun 15;198(12):4607-4617. doi: 10.4049/jimmunol.1600825. Epub 2017 May 15.

17.

Stimulating CD27 to quantitatively and qualitatively shape adaptive immunity to cancer.

Bullock TN.

Curr Opin Immunol. 2017 Apr;45:82-88. doi: 10.1016/j.coi.2017.02.001. Epub 2017 Mar 17. Review.

18.

PD-L1 Expression and Intratumoral Heterogeneity Across Breast Cancer Subtypes and Stages: An Assessment of 245 Primary and 40 Metastatic Tumors.

Dill EA, Gru AA, Atkins KA, Friedman LA, Moore ME, Bullock TN, Cross JV, Dillon PM, Mills AM.

Am J Surg Pathol. 2017 Mar;41(3):334-342. doi: 10.1097/PAS.0000000000000780.

PMID:
28195880
19.

PD-L1, PD-L2 and PD-1 expression in metastatic melanoma: Correlation with tumor-infiltrating immune cells and clinical outcome.

Obeid JM, Erdag G, Smolkin ME, Deacon DH, Patterson JW, Chen L, Bullock TN, Slingluff CL.

Oncoimmunology. 2016 Sep 20;5(11):e1235107. doi: 10.1080/2162402X.2016.1235107. eCollection 2016.

20.

Acute Virus Control Mediated by Licensed NK Cells Sets Primary CD8+ T Cell Dependence on CD27 Costimulation.

Teoh JJ, Gamache AE, Gillespie AL, Stadnisky MD, Yagita H, Bullock TN, Brown MG.

J Immunol. 2016 Dec 1;197(11):4360-4370. Epub 2016 Oct 24.

21.

CD70 and IFN-1 selectively induce eomesodermin or T-bet and synergize to promote CD8+ T-cell responses.

Dong H, Franklin NA, Ritchea SB, Yagita H, Glennie MJ, Bullock TN.

Eur J Immunol. 2015 Dec;45(12):3289-301. doi: 10.1002/eji.201445291. Epub 2015 Nov 6.

22.

IL-27 and the generation of CD8+ T-cell responses to peptide vaccines.

Bullock TN.

Proc Natl Acad Sci U S A. 2014 Nov 25;111(47):16639-40. doi: 10.1073/pnas.1418297111. Epub 2014 Nov 17. No abstract available.

23.

The role of tumor/dendritic cell interactions in the regulation of anti-tumor immunity: the good, the bad, and the ugly.

Hargadon KM, Bullock TN.

Front Immunol. 2014 Apr 16;5:178. doi: 10.3389/fimmu.2014.00178. eCollection 2014. No abstract available.

24.

Metabolic influences that regulate dendritic cell function in tumors.

Dong H, Bullock TN.

Front Immunol. 2014 Jan 30;5:24. doi: 10.3389/fimmu.2014.00024. eCollection 2014. Review.

25.

Editorial: (CD)40 winks to prevent CD8+ T cell lethargy.

Bullock TN.

J Leukoc Biol. 2012 Jun;91(6):845-8. doi: 10.1189/jlb.1211650. No abstract available.

PMID:
22654123
26.

CD27 stimulation promotes the frequency of IL-7 receptor-expressing memory precursors and prevents IL-12-mediated loss of CD8(+) T cell memory in the absence of CD4(+) T cell help.

Dong H, Franklin NA, Roberts DJ, Yagita H, Glennie MJ, Bullock TN.

J Immunol. 2012 Apr 15;188(8):3829-38. doi: 10.4049/jimmunol.1103329. Epub 2012 Mar 14.

27.

Self MHC class I-licensed NK cells enhance adaptive CD8 T-cell viral immunity.

Stadnisky MD, Xie X, Coats ER, Bullock TN, Brown MG.

Blood. 2011 May 12;117(19):5133-41. doi: 10.1182/blood-2010-12-324632. Epub 2011 Mar 23.

28.

Control of established melanoma by CD27 stimulation is associated with enhanced effector function and persistence, and reduced PD-1 expression of tumor infiltrating CD8(+) T cells.

Roberts DJ, Franklin NA, Kingeter LM, Yagita H, Tutt AL, Glennie MJ, Bullock TN.

J Immunother. 2010 Oct;33(8):769-79. doi: 10.1097/CJI.0b013e3181ee238f.

29.

CD70 expression by dendritic cells plays a critical role in the immunogenicity of CD40-independent, CD4+ T cell-dependent, licensed CD8+ T cell responses.

Van Deusen KE, Rajapakse R, Bullock TN.

J Leukoc Biol. 2010 Mar;87(3):477-85. doi: 10.1189/jlb.0809535. Epub 2009 Dec 1.

30.

Strategies and challenges in eliciting immunity to melanoma.

Ferguson AR, Nichols LA, Zarling AL, Thompson ED, Brinkman CC, Hargadon KM, Bullock TN, Engelhard VH.

Immunol Rev. 2008 Apr;222:28-42. doi: 10.1111/j.1600-065X.2008.00620.x.

32.

Incomplete differentiation of antigen-specific CD8 T cells in tumor-draining lymph nodes.

Hargadon KM, Brinkman CC, Sheasley-O'neill SL, Nichols LA, Bullock TN, Engelhard VH.

J Immunol. 2006 Nov 1;177(9):6081-90.

33.

Immunity to melanoma antigens: from self-tolerance to immunotherapy.

Slingluff CL Jr, Chianese-Bullock KA, Bullock TN, Grosh WW, Mullins DW, Nichols L, Olson W, Petroni G, Smolkin M, Engelhard VH.

Adv Immunol. 2006;90:243-95. Review.

PMID:
16730266
37.

Antigens derived from melanocyte differentiation proteins: self-tolerance, autoimmunity, and use for cancer immunotherapy.

Engelhard VH, Bullock TN, Colella TA, Sheasley SL, Mullins DW.

Immunol Rev. 2002 Oct;188:136-46. Review.

PMID:
12445287
38.

Analysis of MHC class II antigen processing by quantitation of peptides that constitute nested sets.

Lippolis JD, White FM, Marto JA, Luckey CJ, Bullock TN, Shabanowitz J, Hunt DF, Engelhard VH.

J Immunol. 2002 Nov 1;169(9):5089-97.

39.

Efficient and qualitatively distinct MHC class I-restricted presentation of antigen targeted to the endoplasmic reticulum.

Golovina TN, Wherry EJ, Bullock TN, Eisenlohr LC.

J Immunol. 2002 Mar 15;168(6):2667-75.

40.
41.
42.

Direct identification of human tumor-associated peptide antigens and a preclinical model to evaluate their use.

Engelhard VH, Bullock TN, Colella TA, Mullins DW.

Cancer J. 2000 May;6 Suppl 3:S272-80. Review.

PMID:
10874498
43.

Self-tolerance to the murine homologue of a tyrosinase-derived melanoma antigen: implications for tumor immunotherapy.

Colella TA, Bullock TN, Russell LB, Mullins DW, Overwijk WW, Luckey CJ, Pierce RA, Restifo NP, Engelhard VH.

J Exp Med. 2000 Apr 3;191(7):1221-32.

44.
45.

Dinitrophenyl-modified autologous melanoma vaccine induces a T cell response to hapten-modified, melanoma peptides.

Sato T, Bullock TN, Eisenlohr LC, Mastrangelo MJ, Berd D.

Clin Immunol Immunopathol. 1997 Dec;85(3):265-72.

PMID:
9400626

Supplemental Content

Loading ...
Support Center